Skip to main content
TECX
NASDAQ Life Sciences

Tectonic Posts Q3 Loss of $21.3M, Cash Runway Into Q1 2029, APEX Data Due January 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.42
Mkt Cap
$379.649M
52W Low
$15.52
52W High
$39.528
52W Position info
25% above low
Off High info
51% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

TECX sits 25% above its 52-week low of $15.52.

Summary

Tectonic reported a $21.3 million Q3 net loss and $234.7 million in cash, enough to fund operations into Q1 2029. The key near-term event is TX45 APEX Phase 2 topline data in PH-HFpEF, expected by the end of January 2027.


Key Events · Earnings and Guidance · TECX

  • Q3 Loss Widens on Higher R&D

    Net loss was $21.3 million versus $19.0 million a year earlier. R&D rose to $17.4 million from $16.9 million, and G&A to $6.0 million from $5.0 million.

  • Cash Runway Into Q1 2029

    Cash and equivalents stood at $234.7 million at September 30, 2026, up from $227.1 million at June 30, 2026, including about $22.3 million of net ATM proceeds raised in the quarter.

  • APEX Phase 2 Data Due January 2027

    Topline results from the TX45 APEX Phase 2 trial in PH-HFpEF are expected by the end of January 2027. Enrollment completed in June 2026, and the IDMC recommended continuing without modification in July 2026.

  • TX2100 Trials Ramp Up

    The TERRA Phase 1b trial in HHT is expected to start by year-end 2026 with interim data by year-end 2027, and the TIDAL Phase 2 trial in moderate-to-severe HHT in early 2027.


Analysis · TECX · Life Sciences

The quarter itself is unremarkable: R&D rose modestly to $17.4 million and the net loss widened to $21.3 million from $19.0 million a year ago. What matters is the balance sheet and the calendar. With $234.7 million of cash funding operations into Q1 2029, past both TX45 Phase 2 readouts, there is no near-term financing need. The single biggest swing factor for the stock is the APEX Phase 2 topline in PH-HFpEF, now guided to the end of January 2027, with ALPINE interim data in the second half of 2027 and TX2100's TERRA trial starting by year-end 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TECX was trading at $19.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.6M. The 52-week trading range was $15.52 to $39.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TECX - Latest Insights

TECX
Nov 05, 2026, 4:39 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.42
Real-time Price: $22.00 info
Change: +$2.58 (+13%) info
Market Cap: $419.707M info
TECX
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $23.51
Real-time Price: $22.00 info
Change: -$1.51 (-6%) info
Market Cap: $419.707M info
TECX
Aug 31, 2026, 10:29 AM EDT
Source: Coinpedia
Importance Score:
7
Price at Filing: $30.88
Real-time Price: $22.00 info
Change: -$8.88 (-29%) info
Market Cap: $419.707M info
TECX
Aug 30, 2026, 2:40 PM EDT
Source: The Block
Importance Score:
9
Price at Filing: $35.62
Real-time Price: $22.00 info
Change: -$13.62 (-38%) info
Market Cap: $419.707M info
TECX
Aug 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.22
Real-time Price: $22.00 info
Change: -$8.22 (-27%) info
Market Cap: $419.707M info